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DRUG QUALITY, SAFETY ISSUES AND THREATS
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ABSTRACT
Until the last decade, the U.S. Food and Drug Administration
(FDA) had tight control over drug importation; principally, drug
manufacturers were the only entities which could legally import
pharmaceuticals. However, in the last ten years, the FDA's tight con-
trol has weakened. The number of U.S. residents who personally im-
port prescription medications has increased dramatically. For exam-
ple, in 2004, over two million U.S. residents purchased over twelve
million prescriptions from Canada alone. The number of prescriptions
purchased from other countries is unknown, but it is estimated that
Americans buy $800 million in drugs from Mexico. Additionally,
drug products are entering the United States from across the globe.
Drug importation not only affects the economy; importation presents
serious drug safety issues for the public. One problem is that some
pharmacy Web sites where individuals obtain their prescription drugs
are rogue, fraudulent sites, with many selling substandard, counterfeit
drug products. Furthermore, many pharmacy Web sites do not require
a prescription and thus some sites are shipping a plethora of narcotic
and non-narcotic drugs to Americans. Thus, medical supervision by
licensed health care practitioners is missing. Some imported products
are of poor quality and are counterfeit. The imported drugs have no
active ingredients, wrong active ingredients, or are poorly labeled and
packaged. However, some imported drug products are FDA-approved
and are the same quality as products from U.S. pharmacies. The prob-
lem is distinguishing the "good" products from the substandard prod-
ucts. However, documentation of the adverse effects from imported,
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substandard medications, including hospitalizations and deaths associ-
ated with imported drug products, is lacking. Furthermore, informa-
tion is lacking regarding the type of drugs being purchased, quantities
and frequency of drug purchases via the Internet or by people crossing
the border, demographic characteristics of the purchasers, and the out-
comes of imported drugs on our health care system. This information
is essential to better determine the risks, and how to address the risks,
of imported drugs. Policy makers need to take a careful look at the in-
formation and investigate the potential impact of drug importation be-
fore setting policy. At this time, drug importation is not the answer to
the U.S. problem of drug access.
INTRODUCTION
Until the 1990s, importation of prescription drugs was very lim-
ited in the United States. If it occurred, it was primarily by people
who lived near either the Mexican or Canadian border. Individuals
living in border communities have been purchasing pharmaceuticals
from Mexico and Canada for decades. In addition, U.S. residents re-
turning home from travels abroad would return with foreign pharma-
ceuticals.
Other than these instances, the U.S. Food and Drug Administra-
tion (FDA) has had a tight grip on the importation of pharmaceuticals.
The only entities that can legally import pharmaceuticals are drug
manufacturers. It is illegal for wholesalers, hospitals, and pharmacies
to import pharmaceuticals for commercial sale. Moreover, it is illegal
for a U.S. resident to import prescription drug products.1
Today the situation has changed dramatically. The FDA's tight
"barbwire" hold now has gaping holes and drug products are entering
the United States from all corners of the world. The FDA's grip on
preventing drug wholesalers, community pharmacies, and hospitals
from importing pharmaceuticals still exists. It is the U.S. resident that
has escaped the FDA's containment. Millions of U.S. residents are
now purchasing pharmaceuticals from foreign pharmacies. In fact, it
is estimated that four percent of the U.S population purchased drugs
from a foreign pharmacy last year.
The development of the World Wide Web and the personal com-
puter has facilitated this change. From their homes, U.S. residents can
order pharmaceuticals from all parts of the globe and have the drug
1. See Federal Food, Drug, and Cosmetic Act 21 U.S.C. §§ 301-399 (2005).
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delivered to their home. Many times no prescription is needed; all one
needs is a credit card number and a mailing address. 2
The driving force pushing U.S. consumers to foreign pharmacies
is the relatively high cost for U.S. brand name pharmaceuticals when
compared to other countries, especially from those countries where
governmental price controls have lowered drug costs.3 Another driv-
ing force behind this movement is the easy access to drugs because in
many parts of the world, "you don't need no stinkin' prescription."
You can purchase a variety of pharmaceuticals, including controlled
substances such as narcotics, antipsychotic, and antidepressant medi-
cations, via the Internet without a prescription.4 Thus, one avoids the
cost associated with seeing a physician to obtain the prescription.
Importantly, some imported drug products are very high quality;
some are FDA-approved and essentially have the same quality as
products found in a U.S. community pharmacy. However, some im-
ported drug products are substandard and poor quality, some are fakes,
and some do not have FDA approval. Some have no active ingredient,
wrong active ingredients, or wrong quantities of the correct active in-
gredient. Some have no labels or are poorly labeled. The problem is
that it is extremely difficult to differentiate between the good quality
products and the substandard products.5
EXTENT OF DRUG IMPORTATION
Easy access to foreign Internet pharmacies has increased the
number of drug products entering the United States dramatically in re-
cent years. From 2003 to 2004, there has been a 1000% increase in
the number of drug packages destined for U.S. residents. The Miami
international mail facility at the Miami International Airport is receiv-
ing up to 30,000 drug-containing packages a day. Chicago O'Hare In-
ternational Airport receives over 4000 drug packages a day, while JFK
Airport in New York receives over 40,000 parcels a day.6 Packages
2. U.S. GEN. ACCOUNTING OFFICE, INTERNET PHARMACIES: SOME POSE SAFETY RISKS
FOR CONSUMERS, GAO Doc. No. 04-820, at 1, 11 (2004), available at http://www.gao.
gov/new.items/d04820.pdf.
3. Buyer Beware: The Danger of Purchasing Pharmaceuticals Over the Internet: Hear-
ings Before the Permanent Subcomm. on Investigations of the S. Comm. on Governmental
Affairs, 108th Cong. 5, 7 (2004) [hereinafter Buyer Beware Hearings] (opening statement of
Sen. Carl Levin).
4. U.S. GEN. ACCOUNTING OFFICE, supra note 2, at 11.
5. See id. at 6-7.
6. Buyer Beware Hearings, supra note 3, at 2-3 (opening statement of Sen. Norm
Coleman).
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are coming from Brazil, India, Pakistan, the Netherlands, Spain,
China, Portugal, Canada, the United Kingdom, Ireland, Mexico, Costa
Rica, Belize, Colombia, the Bahamas, and Honduras, in addition to
many other countries. Clearly, drug products are entering the United
States from across the world.
The United States has fourteen International Mail Branches that
handle all of the U.S. international mail. In addition to these mail fa-
cilities, there are twenty-nine consignment ports and 312 ports of en-
try, all of which handle imported pharmaceuticals. Based on the
above numbers, it is estimated that 20 million packages containing
drug products enter the United States yearly. However, when you in-
clude the number of people crossing the U.S. border, the number may
be much higher. In 2004, it is estimated that close to a billion dollars
worth of drugs were shipped from Canada alone into the United
States, and an estimated $800 million in pharmaceutical sales along
the U.S.-Mexico border.
Since personal importation of a pharmaceutical product is illegal,
the FDA realizes that there may be situations when importation of an
unapproved drug may be necessary and thus the FDA has established
some guidelines for when to enforce the law. These guidelines are
now being followed by Immigration and Customs Enforcement (ICE).
The guidelines suggest not taking action against personal importation
when all of the following are met:
* When the intended use of the unapproved product is "for a
serious condition for which effective treatment" is not
available in the United States.
* "[T]here is no . . . commercialization or promotion to per-
sons residing in the United States by those" distributing
the product.
* The product does not "represent an unreasonable risk."
* The patient has exhausted U.S. treatments and the product
is NOT available in the United States. This is essentially a
last attempt to treat the condition.
" The patient is under a doctor's care for the drug, or started
the treatment outside the United States and is continuing
therapy upon returning to the United States.
* The product is for personal use, not for commercial use.7
Foreign made versions of U.S. drugs are not intended to be cov-
ered by these guidance variances. The FDA views unapproved for-
7. MARVIN A. BLUMBERG, FDA, INFORMATION ON IMPORTATION OF DRUGS, Apr. 3,
1998, http://www.fda.gov/ora/import/pipinfo.htm.
4
California Western International Law Journal, Vol. 36, No. 1 [2005], Art. 9
https://scholarlycommons.law.cwsl.edu/cwilj/vol36/iss1/9
2005] DRUG QUALITY, SAFETY ISSUES AND DRUG IMPORTATION 81
eign made versions of U.S.-approved drugs as an unreasonable risk.
The guidelines express elements of leniency; for example, visitors to
the United States should be allowed to bring their medications with
them when they come to the United States.
Today, these variances have become much broader, and people
are now allowed to import a ninety-day supply of a non-controlled
prescription drug product and fifty units (fifty capsules or tablets) of a
Schedule II through V product. Scheduled or controlled drug products
are narcotic or psychotropic products, products which have a potential
for abuse or are additive.
Various testimonies at congressional hearings show that many
times the quantities of drug products per package coming in from for-
eign sources exceeds the ninety-day supply limitation. Examples in-
clude huge boxes containing many plastic bags, each filled with dif-
ferent colored capsules or tablets; in one instance, none of the bags
had a product identification label. Some of the boxes had thousands
of drug doses, while other parcels only had one drug product that met
the ninety-day supply requirement.
The Bureau of Customs and Border Protection, the FDA, the Drug
Enforcement Administration, ICE, the U.S. Postal Inspection Service,
the Office of National Drug Control Policy, and the Department of
Justice formed a working group to address the issues revolving around
drug importation. This working group investigated the type, volume,
and quality of pharmaceuticals being imported into the United States.
The project was titled "Operation Safeguard," and it was a three-year
investigation ending in 2003. The first "blitz" operation examined im-
ported mailed drug shipments in Miami, New York, San Francisco,
and Carson, California. In this operation, a total of 1153 shipments of
imported drug products were examined. A second series of blitz op-
erations occurred in November of 2003; this blitz occurred at the In-
ternational Mail Branches in Buffalo, Dallas, Chicago, and Seattle. A
total of 3375 drug products were examined from both blitzes. The op-
eration "found the volume of pharmaceuticals shipped through inter-
national mail to be enormous." A summary of the results from both
investigations follows:
" "[A] significant number of [products] [did] not contain an
active pharmaceutical ingredient. . .
" Some products were expired.
" Some products did not have FDA approval.
• Some products had improper directions for use.
" Some products were from "facilities not under proper
regulation."
5
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" Some products were "gray" market or foreign versions of
U.S. approved and patented drug products.
* Some products were unlabeled.
* Some products were improperly packaged. Products re-
quiring refrigeration were not properly packaged.
* Some products were withdrawn from the U.S. market.
* Some products had labels written in a foreign language. 8
Obviously, some imported drug products pose health risks to the
American public. The FDA has issued several warnings to the U.S.
public via public announcements and the FDA Web site about the
risks of purchasing prescription drug products from foreign Web sites.
The FDA's stance is that it is a "buyers beware" market.9
ROGUE PHARMACY WEB SITES AND "BAIT AND SWITCH" TACTICS
There are over a million pharmacy Web sites worldwide where
one can order prescription drug products. Some of these Web sites are
licensed U.S. pharmacies, with some U.S. sites being certified as a
Verified Internet Pharmacy Practice Site (VIPPS). VIPPS certificates
are granted by the U.S. National Association of Boards of Pharmacy
and are only given to those pharmacies that meet stringent certifica-
tion requirements. VIPPS certification seals can be found prominently
displayed on the opening Web page of the pharmacy.' 0 VIPPS certifi-
cation offers consumers added quality assurance.
Many Web-based pharmacies are not located in the United States,
and at times it is very difficult for consumers to determine if the
pharmacy is legitimate and where the pharmacy is located. Rogue,
fraudulent pharmacy Web sites are abundant; additionally, many Web
sites have cascading affiliate Web sites that makes it more difficult to
determine the legitimacy of the pharmacy.
Many Web-based pharmacies do not include an address or a tele-
phone number on the Web site and many use deceptive domain
names. That is, the domain name deceives one to think that the phar-
macy is a legitimate operation located in the United States or another
8. Buyer Beware Hearings, supra note 3, at 220-24 (statement of Jayson P. Ahem, As-
sistant Comm'r, Office of Field Operations, Bureau of Customs and Border Protection).
9. See FDA, BUYING MEDICINES AND MEDICAL PRODUCTS ONLINE,
http://www.fda.gov/buyonline/ (last visited Aug. 13, 2005); JOHN HENKEL, FDA, BUYING
DRUGS ONLINE: IT'S CONVENIENT AND PRIVATE, BUT BEWARE OF "ROGUE SITES," FDA
CONSUMER, Jan.-Feb. 2000, available at http://www. fda.gov/fdac/features/
2000/100_online.html.
10. NAT'L ASS'N OF BOARDS OF PHARMACY, VIPPS, http://www.nabp.net/
vipps/intro.asp? styletag=default (last visited Aug. 13, 2005).
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country, when in fact, it may not be legitimate and it is not located in
the country designated by its domain name. For example, a report re-
leased in June 2005, prepared for the FDA by Cyveillance, a firm
which specializes in online risk management, reported that out of ap-
proximately 11,000 pharmacy Web sites designated Canadian, only
1009 of the sites actually sold prescription drugs, and out of this total
only 214 were located in Canada." I Another study examining the mis-
representation issue, conducted by Global Options, found supposedly
Canadian pharmacy Web sites to be located in Mexico City, Barbados,
and the United States.' 2 Thus, U.S. residents thinking they are getting
a medication from Canada may be getting drug products from another
country. It is the classic "bait and switch" tactic.
What further complicates the issue is that more and more Cana-
dian pharmacy Web sites are transferring U.S. prescriptions to phar-
macies located outside of Canada. The Canadian Web-pharmacy
Canadameds.com recently reported that it was transferring 10,000 pre-
scriptions a week to pharmacies located in thirty different countries
including New Zealand, Germany, Israel, and the United Kingdom.' 3
Thus, even when the site is located in Canada, the drug may come
from another country.
DOCUMENTING PROBLEMS
Documenting the hazards of substandard imported pharmaceuti-
cals is a very difficult task. Deaths and injury from imported pharma-
ceuticals have occurred, but the evidence is anecdotal. When death or
injury does occur, it is usually a special case, such as an overdose of a
narcotic or adverse reaction to the drug.
One must understand that a medication that does not have an ac-
tive ingredient-a fake drug-usually does not kill people, especially
if the product is a treatment for an asymptomatic disease. Another
common problem with fake drugs is the "placebo effect." This occurs
when people believe they are improving because they are taking a
drug product. Many times counterfeit drug makers take advantage of
both factors because they make fake drugs for asymptomatic condi-
11. Press Release, Cyveillance, Cyveillance Helps U.S. Food and Drug Administration
Identify Online Pharmacy Misrepresentation (June 13, 2005), available at http://www. cyveil-
lance.com/web/newsroom/press_rel/2005/2005-06-1 3.htm.
12. GLOBAL OPTIONS, INC., AN ANALYSIS OF TERRORIST THREATS TO AMERICA'S
MEDICINE SUPPLY 145 (2003).
13. Canadameds.com Now Filling Half of All Scripts Overseas, SCRIP WORLD NEWS:
WORLD PHARMACEUTICAL NEWS, Feb. 11, 2005, at 18.
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tions. Examples of this latter category are prophylactic medicinal
products used to lower cholesterol levels or medications to treat high
blood pressure. Many times patients do not feel the illness or the con-
dition. Thus, it may take months, or over a year, before one realizes
that the product to lower cholesterol levels or hypertension medication
was substandard.
In addition, if the patient does not show any improvement, the
physician will either raise the dose of the existing drug or prescribe a
different drug. The possibility that the patient is taking a fake or sub-
standard drug is seldom raised. As mentioned, this can occur with a
wide range of products, and in fact recently occurred with counterfeit
Lipitor. This drug, which controls cholesterol levels, was being pur-
chased by Americans in Mexico's border towns and was found to be
counterfeit after tests showed that it had little effect on the patients'
cholesterol levels. 1
4
Furthermore, if death or morbidity occurs, the result is usually
blamed on the disease. Very seldom is the drug product suspected.
Seldom does one investigate the drugs the patient is taking; they are
assumed to be FDA-approved products. In this sense, it is a perfect
crime. An example of the difficulty of investigating deaths due to a
fake drug is the counterfeit drug case that occurred in June 2005 in
Hamilton, Ontario. 15 Counterfeit Norvasc, a drug used to treat high
blood pressure and angina, was dispensed from a community phar-
macy. A consumer discovered the fake product by noting a slight
color and shape difference in the tablet. Seven people who had pre-
scriptions filled for Norvasc at the pharmacy are dead, leaving little
evidence behind. Six were already buried, one was cremated, and an
autopsy was only done on one person. This case will be a "major fo-
rensic challenge" in determining if the fake drug was the cause of
death. 16
Unless someone suspects foul play, no determination is made as
to whether or not a drug product was involved; the death is conven-
iently blamed on the disease. It is true the death may be due to the
disease, but by not taking the appropriate drug product, the substan-
dard medication may have contributed to the death. The problem is
that no one knows; the data is not being collected.
14. Nick D'Amore, Fake Drugs Sold in Mexico, 24 MED. AD. NEWS 68,68 (2005).
15. Counterfeit Heart Medication Seized From Hamilton Pharmacy by Police,
CANADIAN PRESS, June 16, 2005.
16. Luma Muhtadie, Fake Drug Case: Huge Forensic Challenge, HAMILTON
SPECTATOR, July 16, 2005, at A01.
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Despite the problems of the lack of data, documentation, and
problems with investigating cases involving substandard or fake
pharmaceuticals, deaths and hospitalizations have been reported in the
press due to the imported medication. However, most of these are ei-
ther due to a narcotic drug overdose or the patient had a severe ad-
verse reaction to the product. With the high number of reported coun-
terfeit and substandard drugs being imported, it is difficult to believe
that some Americans have not been affected. The problem lies with
the lack of investigating and documenting the use of imported phar-
maceuticals.
OTHER SAFETY ISSUES WITH DRUG IMPORTATION
Since it takes one to two weeks or even longer to receive an im-
ported medication, most imported drug products are used to treat
chronic conditions, such as arthritis, diabetes, heart conditions, high
cholesterol levels, etc. Importation of medicinal products for acute
care needs is impractical. For acute conditions, people need the medi-
cation now, and they cannot wait two weeks for the therapy. Nor-
mally, patients will use a local community pharmacy to obtain pre-
scription drugs for acute care needs, such as an antibiotic medication.
If this same person purchases his or her chronic care drugs from a
foreign pharmacy, then an added health risk is present. The purchas-
ing of acute care drugs from one pharmacy and chronic care drugs
from a different pharmacy presents added health risks because now
neither pharmacy has a complete record of all the drug products the
patient is taking. Thus, the risk of taking two contraindicated drugs or
the risk of taking a drug that is contraindicated for a disease is much
higher and may result in serious problems for patients. Local commu-
nity pharmacists do maintain an electronic record of all drugs the pa-
tient is taking and pharmacists do use computer programs to help them
screen for drug interactions. Splitting drug therapies between two or
more pharmacies raises the risk of a drug misadventure.
There are other risks associated with purchasing prescription drug
therapies from foreign pharmacies. These include:
* Who does the monitoring of the patient's therapy?
* Who does the patient call if they have drug therapy ques-
tions?
* Who is monitoring the patient's drug compliance?
" Who checks on prescription drug refills and calls the phy-
sician for a refill?
* Who checks for inappropriate therapies?
9
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0 Who is monitoring for duplicate or multiple therapies?
All of the above are critical questions, especially for those patients
who are on multiple drug therapies, including the elderly. The safest
approach for patients is to use one pharmacy and develop a trusting
relationship with the pharmacist. A pharmacy, which has a complete
record of all medications and who can monitor for drug and disease
interactions, can reduce risks and improve the patient's health.
Another safety issue is with the same drug names, but different
ingredients by country. The same drug names may be used in differ-
ent countries, but the active ingredients may be different. For exam-
ple, the U.S. product named Flomax (tamsulosin) is for the treatment
of benign prostate cancer; but in Italy, the product named Flomax con-
tains morniflumate and is a treatment for inflammation, pain, and fe-
ver. Another example is the U.S. product named Norpramin (desip-
ramine), used for the treatment of depression in the United States.
However, in Spain the product called Norpramin contains omeprazole
and is the treatment for peptic ulcers.17 It does raise a concern when a
patient wants a cancer treatment product and receives an entirely dif-
ferent product, but it is not realized because it has the same name.
The name for brand name drugs may differ by country because of lan-
guage translations and negative connotations, or slang used by the cul-
ture.
Lastly, physicians rarely ask where patients obtain their drug
products, assuming patients use FDA-approved products and get their
products from a U.S. pharmacy. Today, physicians must increase
their awareness and ask where their patients are obtaining their drugs,
especially if they see a lack of progress in the patient. What makes
this more difficult is that many patients do not want to admit they are
getting their prescription drugs from a foreign source and thus, they
may not tell the physician they are getting their drugs from Mexico or
somewhere else.
LACK OF DATA ON THE SAFETY AND OUTCOMES OF IMPORTED
PHARMACEUTICALS
The problem is not that imported drugs do not cause problems.
There is enough documentation on the amount of substandard and
counterfeit medications being imported by U.S. residents to realize
that there must be some health consequences. The problem is getting
17. Michael R. Cohen, Drug Trade Names; Something's Lost in Translation, 35
NURSING 12 (2005).
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access to the outcome information and collecting data to document the
problems. This is a tremendous challenge and one that is currently be-
ing exploited by the drug importation businesses.
Foreign drug providers are very reluctant to release drug use data
on the clientele or patient level. Some have released aggregate data,
but this does not address the issues. Even if the data are redacted, for-
eign pharmacy providers will not release the information. Thus, no
information is available as to the type and amount of imported drug
products being purchased by U.S. residents. There is little or no in-
formation as to therapeutic outcomes of people who use foreign-
sourced drug products. There is no information available on the type
of drugs being purchased, broken down by demographic characteristic
of the purchaser. For example, critical questions include:
" What is the average age of the purchasers?
" What is the distribution of drug products by quantity of
drugs or by number of prescriptions dispensed per patient?
* What is the drug product distribution by age or gender?
* What is the geographic location where the purchasers re-
side?
* What is the drug expenditure per prescription, by drug, or
by therapeutic category?
* How many prescriptions are being filled annually per per-
son from a foreign site?
* What are the drug expenditures per person annually?
* What is the repeat business?
* Do Internet drug buyers stay with one provider or do they
shop for drugs worldwide?
Obviously, more research questions can be generated. The point
is that the information is essential to understand drug importation and
its risks, but currently it is unattainable from foreign pharmacies, in-
cluding Canada.
CONCLUSION
Drug importation is a very difficult policy concern. It is not just
an economic issue. There are political issues, international trade con-
cerns, patient liability and legal issues, as well as health concerns, in-
tellectual property protection issues, and the financial implications ex-
pressed by the pharmaceutical industry, community pharmacies, and
the health insurance industry. The legalization of drug importation
will have a huge impact on many U.S. industries. Clearly the situation
is complex. The demand for cheaper prescription drugs will continue.
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For many, lower drug costs have a higher priority than finding afford-
able and safe medications. This country needs to address drug access
and drug pricing directly, rather than using drug importation. Drug
importation is not a long-term solution to the drug access problem.
With the proposed legalization of drug importation, we are not import-
ing drugs-we are importing price controls set by another country. In
addition, we may be importing more public health problems. That is
not a sustainable solution to the problem of access to safe, affordable
medications for the citizens of this country.
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